Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2015
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; Hepatitis C; HIV infections; Liver cirrhosis
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 25 Sep 2015 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 25 Sep 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.